AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14645194 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-E(2) (4 mg/day) from day 20 until next cycle day 2
Number of subjects: 90
Study 14645194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no E(2) pre-treatment)
Number of subjects: 90
Study 14645194 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-E(2) (4 mg/day)
Number of subjects: 90
Study 11012871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental appliance
Number of subjects: 88
Study 11012871 — intervention group
Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 88
Study 8622848 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser treatment
Number of subjects: 320
Study 8622848 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical methods
Number of subjects: 320
Study 8622848 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser
Number of subjects: 320
Study 1468241 — intervention group
Group type: EXPERIMENTAL
Intervention: Audax ear drops
Number of subjects: 36
Study 1468241 — intervention group
Group type: COMPARATOR
Intervention: Earex ear drops
Number of subjects: 36
Study 6693582 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 15
Study 6693582 — intervention group
Group type: COMPARATOR
Intervention: N-desmethylimipramine
Number of subjects: 15
Study 30911578 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐γ 1b
Number of subjects: 92
Study 30911578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 30643809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) infection screening
Number of subjects: 421
Study 30643809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) infection screening
Number of subjects: 421
Study 30643809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic data collection and risk factor analysis
Number of subjects: 421
Study 27439894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and gemcitabine
Number of subjects: 12
Study 24742939 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based constraint induced therapy (CIT)
Number of subjects: 45
Study 24742939 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR)
Number of subjects: 45
Study 22460474 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (PRO, n = 17)
Number of subjects: 33
Study 22460474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, n = 16)
Number of subjects: 33
Study 21179731 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP) with Vaccaria seed before operation and local analgesia on affected limb after operation.
Number of subjects: 60
Study 21179731 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP)
Number of subjects: 60
Study 21179731 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care with celecoxib and local analgesia)
Number of subjects: 60
Study 18630766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single-site thoracic paravertebral block with 25 mL of bupivacaine 0.25% with epinephrine 1:200.000
Number of subjects: 24
Study 18630766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 mL of 0.9% NaCl)
Number of subjects: 24
Study 18630766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single-site thoracic paravertebral block
Number of subjects: 24
Study 16143747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-regulated volume control (PRVC)
Number of subjects: 212
Study 16143747 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 212
Study 11812424 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of water orally administered 30 minutes before verteporfin infusion
Number of subjects: 250
Study 11812424 — intervention group
Group type: COMPARATOR
Intervention: No hydration before therapy
Number of subjects: 250
Study 11812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Total patients
Number of subjects: 250
Study 11812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 250
Study 11143847 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy 40 Gy/17 F/3.2 weeks
Number of subjects: 108
Study 11143847 — intervention group
Group type: COMPARATOR
Intervention: External radiotherapy 45 Gy/20 F/4 weeks
Number of subjects: 108
Study 8843206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level
Number of subjects: 0
Study 8843206 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction in HIV-1 RNA level
Number of subjects: 0
Study 1600686 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride extended-release pellet-filled capsule (240 mg) sprinkled on applesauce
Number of subjects: 32
Study 1600686 — intervention group
Group type: COMPARATOR
Intervention: Verapamil hydrochloride extended-release pellet-filled capsule swallowed intact
Number of subjects: 32
Study 3902237 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen-codeine phosphate combination
Number of subjects: 113
Study 3902237 — intervention group
Group type: COMPARATOR
Intervention: codeine phosphate
Number of subjects: 113
Study 3902237 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 113
Study 31125916 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (cognitive/affective computerized training) in chronic PTSD (N = 48)
Number of subjects: 164
Study 31125916 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (engaging computer games) in chronic PTSD (N = 36)
Number of subjects: 164
Study 30562056 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE training (aerobic exercise intervention)
Number of subjects: 40
Study 30562056 — intervention group
Group type: COMPARATOR
Intervention: Nontraining group (control)
Number of subjects: 40
Study 27544904 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg monotherapy
Number of subjects: 18
Study 27544904 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg combined with desmopressin
Number of subjects: 18
Study 27544904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25377946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) short-term treatment (PAM-S) for 2 weeks
Number of subjects: 60
Study 25377946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) long-term treatment (PAM-L) for 10 weeks
Number of subjects: 60
Study 25377946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) treatment
Number of subjects: 60
Study 25377946 — intervention group
Group type: COMPARATOR
Intervention: ACLT group (control)
Number of subjects: 60
Study 25377946 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM group
Number of subjects: 60
Study 23525511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI)
Number of subjects: 14
Study 23525511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI) with a spacer
Number of subjects: 14
Study 23525511 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate dry-powder inhaler (MF DPI)
Number of subjects: 14
Study 20799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Established guidelines for blood pressure control (EST)
Number of subjects: 762
Study 20799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Established guidelines plus the Dietary Approaches to Stop Hypertension (DASH) dietary pattern (EST + DASH)
Number of subjects: 762
Study 20799005 — intervention group
Group type: COMPARATOR
Intervention: Advice only (ADVICE)
Number of subjects: 762
Study 20799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in dietary intake and weight loss
Number of subjects: 762
Study 20799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in physical activity
Number of subjects: 762
Study 20799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in sodium and low-fat dairy intake
Number of subjects: 762
Study 27408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Releasing Intrauterine System (LNG‐IUS)
Number of subjects: 70
Study 27408116 — intervention group
Group type: COMPARATOR
Intervention: Copper T device (Cu T)
Number of subjects: 70
Study 15705477 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg CRM197-Hib conjugate
Number of subjects: 261
Study 15705477 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg CRM197-Hib conjugate
Number of subjects: 261
Study 15705477 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg CRM197-Hib conjugate
Number of subjects: 261
Study 15705477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 microg CRM197-Hib conjugate
Number of subjects: 261
Study 12602669 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 1214
Study 12602669 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 1214
Study 12602669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study 10526997 — intervention group
Group type: EXPERIMENTAL
Intervention: IQOLA version of SF36 health survey
Number of subjects: 946
Study 10526997 — intervention group
Group type: COMPARATOR
Intervention: Geneva version of SF36 health survey
Number of subjects: 946
Study 8784214 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 8784214 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0
Study 8784214 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 0
Study 8784214 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 0
Study 1971636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 268
Study 1971636 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 268
Study 1971636 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (ampicillin, gentamicin, metronidazole)
Number of subjects: 268
Study 6993259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-lymphocytic globulin (ALG) 1 g daily for 5 days
Number of subjects: 10
Study 6993259 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with corticosteroids
Number of subjects: 10
Study 31505220 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie information displayed on menus
Number of subjects: 0
Study 31505220 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie information displayed just to the right of the price
Number of subjects: 0
Study 31505220 — intervention group
Group type: COMPARATOR
Intervention: Calorie information presence
Number of subjects: 0
Study 31505220 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking data
Number of subjects: 0
Study 31505220 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie posting
Number of subjects: 0
Study 31505220 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of the meal
Number of subjects: 0
Study 31159780 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting lifestyle counselling (3 sessions of 45 minutes each)
Number of subjects: 102
Study 31159780 — intervention group
Group type: COMPARATOR
Intervention: Routine care provided by health centers (Control)
Number of subjects: 102
Study 28237866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CAP-B) maintenance therapy
Number of subjects: 558
Study 28237866 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 558
Study 28237866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CAP-B) maintenance therapy in patients with complete or partial response
Number of subjects: 558
Study 25468946 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite matching 2-hydroxybiphenyl
Number of subjects: 431
Study 25468946 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolites matching PC (22:6/20:4), (3S)-7-hydroxy-2',3',4',5',8-pentamethoxyisoflavan, or tetrapeptides
Number of subjects: 431
Study 25468946 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker score comprising all seven metabolites
Number of subjects: 431
Study 24968526 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐‐alpha2B
Number of subjects: 80
Study 24968526 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 80
Study 21425519 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention (watchful waiting, minimally supported CBT-based self-help intervention, problem-solving treatment, referral to a primary care physician for medication if required)
Number of subjects: 170
Study 21425519 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study 19263200 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (IC) for cardiac output (CO) measurements
Number of subjects: 24
Study 19263200 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing with optimized VV intervals
Number of subjects: 24
Study 19263200 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal VV interval programmed according to IC measurements
Number of subjects: 24
Study 19263200 — intervention group
Group type: COMPARATOR
Intervention: Comparison of optimal VV intervals identified by IC and LV dP/dt(max)
Number of subjects: 24
Study 19263200 — intervention group
Group type: COMPARATOR
Intervention: Broader VV time intervals comparison
Number of subjects: 24
Study 17289236 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot antipsychotics (DA)
Number of subjects: 505
Study 17289236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 505
Study 17289236 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, number of hospitalizations, site, and use of DA
Number of subjects: 505
Study 17289236 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP), depot antipsychotics (DA), and clozapine
Number of subjects: 505
Study 15285600 — intervention group
Group type: EXPERIMENTAL
Intervention: Credibility of promises
Number of subjects: 0
Study 15285600 — intervention group
Group type: EXPERIMENTAL
Intervention: Credibility of threats
Number of subjects: 0
Study 11680799 — intervention group
Group type: COMPARATOR
Intervention: Healthy females (control group)
Number of subjects: 482
Study 11680799 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with early menopause
Number of subjects: 482
Study 9770089 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (Disoprifusor-TCI)
Number of subjects: 21
Study 9770089 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion
Number of subjects: 21
Study 7861598 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O PSV
Number of subjects: 9
Study 7861598 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O PSV + 5 cmH2O PEEP
Number of subjects: 9
Study 7861598 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia circle system (control)
Number of subjects: 9
Study 2582842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing air
Number of subjects: 6
Study 2582842 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 6
Study 1012896 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning 80% of contests
Number of subjects: 0
Study 1012896 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning 50% of contests
Number of subjects: 0
Study 1012896 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning 20% of contests
Number of subjects: 0
Study 1012896 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive trait anxiety (high vs low)
Number of subjects: 0
Study 31685272 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaortic OPCAB (ANA) with total arterial revascularization
Number of subjects: 192
Study 31685272 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB with vein grafts using carbon dioxide surgical field flooding (CO2FF)
Number of subjects: 192
Study 31685272 — intervention group
Group type: COMPARATOR
Intervention: Conventional OPCAB with vein grafts (Control)
Number of subjects: 192
Study 31498183 — intervention group
Group type: EXPERIMENTAL
Intervention: ST‐PD
Number of subjects: 153
Study 31498183 — intervention group
Group type: COMPARATOR
Intervention: AFA‐PD
Number of subjects: 153
Study 28693998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 or 150 mg, given every 2 weeks
Number of subjects: 4212
Study 28693998 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4212
Study 28693998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 or 150 mg
Number of subjects: 4212
Study 28693998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4212
Study 26048739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile platforms
Number of subjects: 0
Study 26048739 — intervention group
Group type: COMPARATOR
Intervention: Stationary computer
Number of subjects: 0
Study 26048739 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sized devices
Number of subjects: 0
Study 26048739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary and tablet platforms
Number of subjects: 0
Study 23811187 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Number of subjects: 54
Study 23811187 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 54
Study 23811187 — intervention group
Group type: COMPARATOR
Intervention: Control (lean females)
Number of subjects: 54
Study 21058940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-only sedation (group P)
Number of subjects: 64
Study 21058940 — intervention group
Group type: COMPARATOR
Intervention: Propofol-alfentanil combination sedation (group PA)
Number of subjects: 64
Study 18676412 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV with full PSV (PS(max))
Number of subjects: 10
Study 18676412 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV with partial PSV (PS(min))
Number of subjects: 10
Study 18676412 — intervention group
Group type: COMPARATOR
Intervention: SIMV alone
Number of subjects: 10
Study 17701962 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic perforator surgery (SEPS)
Number of subjects: 72
Study 17701962 — intervention group
Group type: COMPARATOR
Intervention: No SEPS (standard surgery: saphenofemoral ligation, stripping and phlebectomies)
Number of subjects: 72
Study 15119171 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at bilateral Neiguan (PC 6) plus oral administration of mexiletine
Number of subjects: 60
Study 15119171 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of mexiletine
Number of subjects: 60
Study 11702162 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol (300 mg/ml), 120 ml
Number of subjects: 146
Study 11702162 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (300 mg/ml), 120 ml
Number of subjects: 146
Study 11702162 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol and Iohexol
Number of subjects: 146
Study 9520247 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stimulation first group (exposed to pain induction by ice water and pressure prior to sham stimulation)
Number of subjects: 0
Study 9520247 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation first group (received sham stimulation followed by cold water and pressure pain induction)
Number of subjects: 0
Study 9520247 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stimulation first group
Number of subjects: 0
Study 9520247 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation first group
Number of subjects: 0
Study 8035030 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP‐2 (50 micrograms)
Number of subjects: 6
Study 8035030 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6
Study 8035030 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP‐2
Number of subjects: 6
Study 2500141 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C 15 mg/m2 plus DSM 360 mg administered into the hepatic artery (group I)
Number of subjects: 63
Study 2500141 — intervention group
Group type: COMPARATOR
Intervention: mitomycin C 15 mg/m2 (group II)
Number of subjects: 63
Study 29886318 — intervention group
Group type: EXPERIMENTAL
Intervention: Push back maneuver
Number of subjects: 945
Study 29886318 — intervention group
Group type: COMPARATOR
Intervention: Standard vaginal delivery
Number of subjects: 945
Study 28224449 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson 0.4 mg during recovery (Ex-Reg)
Number of subjects: 1147
Study 28224449 — intervention group
Group type: COMPARATOR
Intervention: Regadenoson 0.4 mg 1 hour after inadequate exercise (Regadenoson)
Number of subjects: 1147
Study 26195123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100 mg)
Number of subjects: 166
Study 26195123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.6 g glycerin suppository)
Number of subjects: 166
Study 24299497 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules for 8 months
Number of subjects: 130
Study 24299497 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo capsules for 8 months
Number of subjects: 130
Study 21441258 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI‐2 validity scales
Number of subjects: 103
Study 18488442 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor intervention performed by Pello the clown triggering regular laughter
Number of subjects: 19
Study 18488442 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor intervention
Number of subjects: 19
Study 18488442 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls, n = 10)
Number of subjects: 19
Study 16545638 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg folic acid daily
Number of subjects: 315
Study 16545638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 12943949 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day) plus Lithium Carbonate (750 mg/day)
Number of subjects: 141
Study 12943949 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day) plus Placebo
Number of subjects: 141